Once again, with the aid of Gilead’s experimental GS-5734, and ZMappTM — from Mapp Bio Pharmaceuticals, a likely fatal case was arrested.
We saw much the same in the resurgent (and now vanquished) case of Pauline Cafferkey, last month, in London. Though little Nubia will grow up without her mother — she will, in all likelihood, actually grow up. And in 42 days, Guinea will be declared disease free (again). All from Reuters United Kingdom, just this quiet Saturday afternoon:
. . . .A one-month-old baby girl who was Guinea’s last reported Ebola case left hospital on Saturday, delighting medical staff and putting the country on course to be declared free of the deadly virus.
Guinea will become officially Ebola-free after 42 days if no new cases are reported following the recovery of baby Nubia — thought to be the first baby to survive after being born to an infected mother. . . .
Nubia, who was born Ebola-positive and named after an MSF nurse, was able to survive due to experimental drugs as well as round-the-clock care given by a 20-strong team.
“When she (Nubia) started having convulsions, we thought the virus had entered the brain and that’s when we started the anti-viral,” Sailly said. “Everyone was following hour by hour.”
Sailly said Nubia had received Mapp Biopharmaceutical Inc’s Ebola drug ZMapp as well as an experimental anti-viral drug known as GS-5734 being developed by the U.S. drugmaker Gilead Sciences. . . .
We will keep you posted, here, just as we wish all babies, the world over. . . long lives, and great health!